Skip to main content
Caplight Logo









Apersys AG

Apersys AG

Private
ZurichHealthcare & Life Scienceshttps://apersys.com

Last Round

Series A

Dec 9, 2024

Total Funding Raised

$12.78M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Apersys AG operates in Healthcare & Life Sciences and is based in Zurich. Its latest recorded funding round was a Series A round in December 2024.

Apersys AG is a medical technology company that develops and manufactures a novel long-term normothermic organ perfusion system designed to preserve and assess livers outside the human body.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology

Business Model

B2B

Customer Profile

Hardware Sales, Hardware + Subscription, Services & Consulting

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Apersys AG Comparables

Compare Apersys AG with similar companies based on industry and business-model similarity.

Apersys AG comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Terumo Corporation
79%
Getinge AB
78%
Xvivo Perfusion
76%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Apersys AG Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ADec 9, 2024
SeedOct 25, 2024
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 10, 2026

    Open roles increased to 5, 3.6x the trailing average.

  • Aug 3, 2026

    Open roles increased to 3, 3x the trailing average.

Book a demo to see all signals

For institutional investors. Book with your work email.

Apersys AG Filings

Explore SEC and related filing metadata, where available.

Apersys AG filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Apersys AG's valuation, stock price, and market status.

Is Apersys AG a public or private company?

Apersys AG is a private company.

What is the current stock price of Apersys AG?

Apersys AG is a private company, so its shares have no public market price. Caplight tracks Apersys AG's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Apersys AG worth (valuation)?

Valuation information for Apersys AG is not publicly available.

Can I buy Apersys AG stock?

Apersys AG shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Apersys AG's last funding round?

Apersys AG's most recent funding round was Series A on December 9, 2024.

Who are the main investors in Apersys AG?

Investor information for Apersys AG is not publicly disclosed.

Will Apersys AG IPO soon?

No public IPO plans have been announced for Apersys AG.

How can I track Apersys AG secondary market activity?

Caplight tracks bids, offers, and trades in Apersys AG's shares on secondary markets.

Firmographic Details

HeadquartersZurich
Employee Range8
Year Founded2024
Last FundingDec 9, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?